Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY: OGN )

15.83 -0.05 (-0.31%)
Streaming Delayed Price Updated: 10:29 AM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Organon & Co. Common Stock

< Previous 1 2 3 Next >
Organon Reports Results for the Third Quarter Ended September 30, 2023
From Organon & Co.
Via Business Wire
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
From Organon & Co.
Via Business Wire
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
From Organon & Co.
Via Business Wire
Lululemon Athletica Races to New High with S&P 500 Entry
Lululemon's stock soared 10.31%, its best level since late 2021, upon joining the S&P 500, replacing Activision Blizzard. The change is effective October 18. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
From Organon & Co.
Via Business Wire
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
From Organon & Co.
Via Business Wire
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
From Organon & Co.
Via Business Wire
Organon Reports Results for the Second Quarter Ended June 30, 2023
From Organon & Co.
Via Business Wire
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
From Samsung Bioepis
Via GlobeNewswire
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
From Organon & Co.
Via Business Wire
REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
From Organon
Via Business Wire
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
From Organon & Co.
Via Business Wire
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
From Organon & Co.
Via Business Wire
Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
From Organon & Co.
Via Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2023
From Organon & Co.
Via Business Wire
Organon To Report First Quarter and Host Conference Call on May 4, 2023
From Organon & Co.
Via Business Wire
Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
From Organon & Co.
Via Business Wire
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
From Organon
Via Business Wire
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
From Organon & Co.
Via Business Wire
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
From Organon & Co.
Via Business Wire
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
From Organon & Co.
Via Business Wire
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2022
From Organon & Co.
Via Business Wire
Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
From Organon & Co.
Via Business Wire
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
From Organon & Co.
Via Business Wire
Organon Reports Results for the Second Quarter Ended June 30, 2022
From Organon & Co.
Via Business Wire
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
From Organon & Co.
Via Business Wire
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
From Organon & Co.
Via Business Wire
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
From Organon & Co.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.